;PMID: 7488489 ;source_file_1901.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..35] = [t:0..35] ;1)sentence:[e:41..207] = [t:41..207] ;2)section:[e:211..255] = [t:211..255] ;3)section:[e:259..378] = [t:259..378] ;4)sentence:[e:382..527] = [t:382..527] ;5)sentence:[e:528..650] = [t:528..650] ;6)sentence:[e:651..714] = [t:651..714] ;7)sentence:[e:715..894] = [t:715..894] ;8)sentence:[e:895..975] = [t:895..975] ;9)sentence:[e:976..1142] = [t:976..1142] ;10)sentence:[e:1143..1264] = [t:1143..1264] ;11)sentence:[e:1265..1419] = [t:1265..1419] ;12)sentence:[e:1420..1607] = [t:1420..1607] ;13)section:[e:1611..1655] = [t:1611..1655] ;section 0 Span:0..35 ;Br J Anaesth. 1995 Oct;75(4):462-6. (SEC (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..12] Anaesth) (.:[12..13] .) (CD:[14..18] 1995) (.:[19..25] Oct;75) (-LRB-:[25..26] -LRB-) (CD:[26..27] 4) (-RRB-:[27..28] -RRB-) (CD:[28..35] :462-6.))) ;sentence 1 Span:41..207 ;Difference between in vivo and in vitro effects of propofol on defluorination ; and metabolic activities of hamster hepatic cytochrome P450-dependent ;mono-oxygenases. ;[92..100]:substance:"propofol" ;[164..179]:cyp450:"cytochrome P450" ;[191..206]:substance:"mono-oxygenases" (SENT (NP-HLN (NP (NN:[41..51] Difference)) (PP (IN:[52..59] between) (NP (NP (NP (NP (ADJP (FW:[60..62] in) (FW:[63..67] vivo)) (NML-2 (-NONE-:[67..67] *P*))) (CC:[68..71] and) (NP (ADJP (FW:[72..74] in) (FW:[75..80] vitro)) (NML-2 (NNS:[81..88] effects)))) (PP (IN:[89..91] of) (NP (NN:[92..100] propofol)))) (PP (IN:[101..103] on) (NP (NP (NP (NN:[104..118] defluorination)) (CC:[120..123] and) (NP (JJ:[124..133] metabolic) (NNS:[134..144] activities))) (PP (IN:[145..147] of) (NP (NN:[148..155] hamster) (JJ:[156..163] hepatic) (NML (NML (NN:[164..174] cytochrome) (NN:[175..179] P450)) (HYPH:[179..180] -) (JJ:[180..189] dependent)) (AFX:[191..195] mono) (HYPH:[195..196] -) (NNS:[196..206] oxygenases))))))) (.:[206..207] .))) ;section 2 Span:211..255 ;Chen TL, Wang MJ, Huang CH, Liu CC, Ueng TH. (SEC (FRAG (NNP:[211..215] Chen) (NNP:[216..218] TL) (,:[218..219] ,) (NNP:[220..224] Wang) (NNP:[225..227] MJ) (,:[227..228] ,) (NNP:[229..234] Huang) (NNP:[235..237] CH) (,:[237..238] ,) (NNP:[239..242] Liu) (NNP:[243..245] CC) (,:[245..246] ,) (NNP:[247..251] Ueng) (NNP:[252..254] TH) (.:[254..255] .))) ;section 3 Span:259..378 ;Department of Anaesthesia, College of Medicine, National Taiwan University ;Hospital, No. 7, Taipei, Republic of China. (SEC (FRAG (NNP:[259..269] Department) (IN:[270..272] of) (NNP:[273..284] Anaesthesia) (,:[284..285] ,) (NNP:[286..293] College) (IN:[294..296] of) (NNP:[297..305] Medicine) (,:[305..306] ,) (NNP:[307..315] National) (NNP:[316..322] Taiwan) (NNP:[323..333] University) (NNP:[335..343] Hospital) (,:[343..344] ,) (NNP:[345..347] No) (.:[347..348] .) (CD:[349..350] 7) (,:[350..351] ,) (NNP:[352..358] Taipei) (,:[358..359] ,) (NNP:[360..368] Republic) (IN:[369..371] of) (NNP:[372..377] China) (.:[377..378] .))) ;sentence 4 Span:382..527 ;We have compared the in vivo and in vitro effects of propofol on cytochrome ;P450-dependent monooxygenase activities in hamster liver microsomes. ;[435..443]:substance:"propofol" ;[447..463]:cyp450:"cytochrome P450" ;[474..487]:substance:"monooxygenase" (SENT (S (NP-SBJ (PRP:[382..384] We)) (VP (VBP:[385..389] have) (VP (VBN:[390..398] compared) (NP (NP (DT:[399..402] the) (NML (NML (ADJP (FW:[403..405] in) (FW:[406..410] vivo)) (NML-1 (-NONE-:[410..410] *P*))) (CC:[411..414] and) (NML (ADJP (FW:[415..417] in) (FW:[418..423] vitro)) (NML-1 (NNS:[424..431] effects))))) (PP (IN:[432..434] of) (NP (NN:[435..443] propofol))) (PP (IN:[444..446] on) (NP (ADJP (NML (NN:[447..457] cytochrome) (NN:[459..463] P450)) (HYPH:[463..464] -) (JJ:[464..473] dependent)) (NN:[474..487] monooxygenase) (NNS:[488..498] activities)))) (PP-LOC (IN:[499..501] in) (NP (NN:[502..509] hamster) (NN:[510..515] liver) (NNS:[516..526] microsomes))))) (.:[526..527] .))) ;sentence 5 Span:528..650 ;Propofol (Diprivan) 10 mg/100 g body weight was injected i.p. twice a day ;for 2 weeks to induce cytochrome P450 enzymes. ;[528..536]:substance:"Propofol" ;[539..547]:substance:"Diprivan" ;[549..551]:quantitative-value:"10" ;[552..572]:quantitative-value:"mg/100 g body weight" ;[607..608]:quantitative-value:"2" ;[609..614]:quantitative-units:"weeks" ;[626..649]:cyp450:"cytochrome P450 enzymes" (SENT (S (NP-SBJ-1 (NP (NP (NN:[528..536] Propofol)) (NP (-LRB-:[538..539] -LRB-) (NN:[539..547] Diprivan) (-RRB-:[547..548] -RRB-))) (NP-MNR (NP (CD:[549..551] 10) (NN:[552..554] mg)) (PP (SYM:[554..555] /) (NP (NML (CD:[555..558] 100) (NN:[559..560] g)) (NN:[561..565] body) (NN:[566..572] weight))))) (VP (VBD:[573..576] was) (VP (VBN:[577..585] injected) (NP-1 (-NONE-:[585..585] *)) (ADVP (RB:[586..590] i.p.)) (ADVP-TMP (RB:[591..596] twice) (NP (DT:[597..598] a) (NN:[599..602] day))) (PP-TMP (IN:[603..606] for) (NP (CD:[607..608] 2) (NNS:[609..614] weeks))) (S-PRP (NP-SBJ (-NONE-:[614..614] *)) (VP (TO:[615..617] to) (VP (VB:[619..625] induce) (NP (NML (NN:[626..636] cytochrome) (NN:[637..641] P450)) (NNS:[642..649] enzymes))))))) (.:[649..650] .))) ;sentence 6 Span:651..714 ;Liver microsomes were prepared by differential centrifugation. (SENT (S (NP-SBJ-1 (NN:[651..656] Liver) (NNS:[657..667] microsomes)) (VP (VBD:[668..672] were) (VP (VBN:[673..681] prepared) (NP-1 (-NONE-:[681..681] *)) (PP-MNR (IN:[682..684] by) (NP (JJ:[685..697] differential) (NN:[699..713] centrifugation))))) (.:[713..714] .))) ;sentence 7 Span:715..894 ;Metabolism of the cytochrome P450-dependent mono-oxygenase system was ;evaluated by measuring aniline hydroxylation, benzphetamine demethylation ;and benzo(a)pyrene hydroxylation. ;[733..748]:cyp450:"cytochrome P450" ;[759..773]:substance:"mono-oxygenase" ;[809..816]:substance:"aniline" ;[832..845]:substance:"benzphetamine" ;[865..879]:substance:"benzo(a)pyrene" (SENT (S (NP-SBJ-1 (NP (NN:[715..725] Metabolism)) (PP (IN:[726..728] of) (NP (DT:[729..732] the) (ADJP (NML (NN:[733..743] cytochrome) (NN:[744..748] P450)) (HYPH:[748..749] -) (JJ:[749..758] dependent)) (NML (AFX:[759..763] mono) (HYPH:[763..764] -) (NN:[764..773] oxygenase)) (NN:[775..781] system)))) (VP (VBD:[782..785] was) (VP (VBN:[786..795] evaluated) (NP-1 (-NONE-:[795..795] *)) (PP-MNR (IN:[796..798] by) (S-NOM (NP-SBJ (-NONE-:[798..798] *)) (VP (VBG:[799..808] measuring) (NP (NP (NN:[809..816] aniline) (NN:[817..830] hydroxylation)) (,:[830..831] ,) (NP (NN:[832..845] benzphetamine) (NN:[847..860] demethylation)) (CC:[861..864] and) (NP (NN:[865..879] benzo-LRB-a-RRB-pyrene) (NN:[880..893] hydroxylation)))))))) (.:[893..894] .))) ;sentence 8 Span:895..975 ;Defluorination of enflurane was assayed by detecting free fluoride ;metabolites. ;[913..922]:substance:"enflurane" ;[954..974]:substance:"fluoride metabolites" (SENT (S (NP-SBJ-1 (NP (NN:[895..909] Defluorination)) (PP (IN:[910..912] of) (NP (NN:[913..922] enflurane)))) (VP (VBD:[923..926] was) (VP (VBN:[928..935] assayed) (NP-1 (-NONE-:[935..935] *)) (PP-MNR (IN:[936..938] by) (S-NOM (NP-SBJ (-NONE-:[938..938] *)) (VP (VBG:[939..948] detecting) (NP (JJ:[949..953] free) (NN:[954..962] fluoride) (NNS:[963..974] metabolites))))))) (.:[974..975] .))) ;sentence 9 Span:976..1142 ;At similar concentrations as in the in vivo group, propofol in vitro ;exhibited concentration-dependent inhibition of metabolism of benzphetamine ;and benzo(a)pyrene. ;[1028..1036]:substance:"propofol" ;[1109..1122]:substance:"benzphetamine" ;[1127..1141]:substance:"benzo(a)pyrene" (SENT (S (PP (IN:[976..978] At) (NP (NP (JJ:[979..986] similar) (NNS:[987..1001] concentrations)) (PP (IN:[1002..1004] as) (PP-LOC (IN:[1005..1007] in) (NP (DT:[1009..1012] the) (ADJP (FW:[1013..1015] in) (FW:[1016..1020] vivo)) (NN:[1021..1026] group)))))) (,:[1026..1027] ,) (NP-SBJ (NP (NN:[1028..1036] propofol)) (ADJP (FW:[1037..1039] in) (FW:[1040..1045] vitro))) (VP (VBD:[1046..1055] exhibited) (NP (NP (ADJP (NN:[1056..1069] concentration) (HYPH:[1069..1070] -) (JJ:[1070..1079] dependent)) (NN:[1081..1091] inhibition)) (PP (IN:[1092..1094] of) (NP (NP (NN:[1095..1105] metabolism)) (PP (IN:[1106..1108] of) (NP (NN:[1109..1122] benzphetamine) (CC:[1123..1126] and) (NN:[1127..1141] benzo-LRB-a-RRB-pyrene))))))) (.:[1141..1142] .))) ;sentence 10 Span:1143..1264 ;Aniline hydroxylation and defluorination of enflurane were inhibited to 78% ;of control with propofol 0.25 mmol litre-1. ;[1143..1150]:substance:"Aniline" ;[1188..1197]:substance:"enflurane" ;[1216..1219]:quantitative-value:"78%" ;[1237..1245]:substance:"propofol" ;[1246..1250]:quantitative-value:"0.25" ;[1251..1263]:quantitative-units:"mmol litre-1" (SENT (S (NP-SBJ-1 (NP (NN:[1143..1150] Aniline) (NN:[1152..1165] hydroxylation)) (CC:[1166..1169] and) (NP (NP (NN:[1170..1184] defluorination)) (PP (IN:[1185..1187] of) (NP (NN:[1188..1197] enflurane))))) (VP (VBD:[1198..1202] were) (VP (VBN:[1203..1212] inhibited) (NP-1 (-NONE-:[1212..1212] *)) (PP-EXT (TO:[1213..1215] to) (NP (NP (CD:[1216..1218] 78) (NN:[1218..1219] %)) (PP (IN:[1220..1222] of) (NP (NN:[1223..1230] control))))) (PP-MNR (IN:[1232..1236] with) (NP (NP (NN:[1237..1245] propofol)) (NP (NML (CD:[1246..1250] 0.25) (NN:[1251..1255] mmol)) (NN:[1256..1263] litre-1)))))) (.:[1263..1264] .))) ;sentence 11 Span:1265..1419 ;In propofol-treated hamsters, there was only minimal inhibitory or inductive ;effects on either mono-oxygenase activities or capacity for defluorination. ;[1268..1276]:substance:"propofol" ;[1361..1375]:substance:"mono-oxygenase" (SENT (S (PP-LOC (IN:[1265..1267] In) (NP (ADJP (NN:[1268..1276] propofol) (HYPH:[1276..1277] -) (VBN:[1277..1284] treated)) (NNS:[1285..1293] hamsters))) (,:[1293..1294] ,) (NP-SBJ (EX:[1295..1300] there)) (VP (VBD:[1301..1304] was) (NP-PRD (NP (RB:[1305..1309] only) (NP (ADJP-1 (JJ:[1311..1318] minimal)) (JJ:[1319..1329] inhibitory) (NML-2 (-NONE-:[1329..1329] *P*))) (CC:[1330..1332] or) (NP (ADJP-1 (-NONE-:[1332..1332] *P*)) (JJ:[1333..1342] inductive) (NML-2 (NNS:[1343..1350] effects)))) (PP (IN:[1351..1353] on) (NP (CC:[1354..1360] either) (NP (NML (AFX:[1361..1365] mono) (HYPH:[1365..1366] -) (NN:[1366..1375] oxygenase)) (NNS:[1376..1386] activities)) (CC:[1387..1389] or) (NP (NP (NN:[1391..1399] capacity)) (PP (IN:[1400..1403] for) (NP (NN:[1404..1418] defluorination)))))))) (.:[1418..1419] .))) ;sentence 12 Span:1420..1607 ;This difference between the in vitro and in vivo effects of propofol on ;cytochrome P450 mono-oxygenase activities emphasizes the need for care when ;comparing in vitro and clinical data. ;[1481..1489]:substance:"propofol" ;[1493..1508]:cyp450:"cytochrome P450" ;[1509..1523]:substance:"mono-oxygenase" (SENT (S (NP-SBJ (NP (DT:[1420..1424] This) (NN:[1425..1435] difference)) (PP (IN:[1436..1443] between) (NP (NP (DT:[1444..1447] the) (NML (NML (ADJP (FW:[1448..1450] in) (FW:[1451..1456] vitro)) (NML-2 (-NONE-:[1456..1456] *P*))) (CC:[1457..1460] and) (NML (ADJP (FW:[1461..1463] in) (FW:[1464..1468] vivo)) (NML-2 (NNS:[1470..1477] effects))))) (PP (IN:[1478..1480] of) (NP (NN:[1481..1489] propofol))) (PP (IN:[1490..1492] on) (NP (NML (NN:[1493..1503] cytochrome) (NN:[1504..1508] P450)) (NML (AFX:[1509..1513] mono) (HYPH:[1513..1514] -) (NN:[1514..1523] oxygenase)) (NNS:[1524..1534] activities)))))) (VP (VBZ:[1535..1545] emphasizes) (NP (NP (DT:[1546..1549] the) (NN:[1551..1555] need)) (PP (IN:[1556..1559] for) (NP (NN:[1560..1564] care)))) (SBAR-ADV (WRB:[1565..1569] when) (S (NP-SBJ (-NONE-:[1569..1569] *)) (VP (VBG:[1570..1579] comparing) (NP (ADJP (FW:[1580..1582] in) (FW:[1583..1588] vitro)) (NML-1 (-NONE-:[1588..1588] *P*))) (CC:[1589..1592] and) (NP (JJ:[1593..1601] clinical) (NML-1 (NNS:[1602..1606] data))))))) (.:[1606..1607] .))) ;section 13 Span:1611..1655 ;PMID: 7488489 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1611..1615] PMID) (::[1615..1616] :) (CD:[1617..1624] 7488489) (NN:[1625..1626] -LSB-) (NNP:[1626..1632] PubMed) (HYPH:[1633..1634] -) (NN:[1635..1642] indexed) (IN:[1643..1646] for) (NNP:[1647..1654] MEDLINE) (-RRB-:[1654..1655] -RSB-)))